TruScreen Annual Meeting of Shareholders- Results

NZX and Media Release 27 September 2018 NZX Limited WELLINGTON TruScreen Limited Results of Annual Shareholder Meeting The TruScreen Limited (NZAX: TRU) Annual Meeting of shareholders was held on 27 September 2018. The company updated shareholders on its positive performance in the year to date as it continues to make good commercial progress in its target markets, increase sales and expand its global footprint. A number of large scale evaluations are underway in China and the company has commenced an evaluation for TruScreen in Africa with the National Aids Council of Zimbabwe. Sales of both the TruScreen device and single use sensors are tracking well ahead of last year, with ongoing demand from China and other markets. Voting was conducted by poll of the shareholders present at the meeting and the proxies registered. Details of the resolutions and voting results were: Resolutions. Authorise Directors to fix the auditor's remuneration: Passed For: 166,940,051. 99.97% Against: 50,000. 0.03% Abstain: 94,946 Re-election of Mr Robert Hunter as a Director: Passed For: 142,235,926. 89.38% Against: 17,738,625 10.62% Abstain: 110,446 Election of Professor Ronald Jones as a Director: Passed For: 108,719,551. 99.72% Against: 300,000. 0.28% Abstain: 58,065,446 Election of Mr Chris Lawrence as a Director: Passed For: 108,719,551. 99.72% Against: 300,000. 0.28% Abstain: 58,065,446 Election of Ms Marie Ficarra as a Director: Withdrawn Election of Mr Kelly (Con) Hickey as a Director: Passed For: 108,448,551. 99.49% Against: 560,000. 0.51% Abstain: 58,065,446 Election of Mr Anthony Ho as a Director: Passed For: 108,449,551. 99.49% Against: 560,000. 0.51% Abstain: 58,075,446 In accordance with the NZAX listing rule 3.2.1, three directors, Ron Jones, Chris Lawrence and Kelly (Con) Hickey, are ordinarily resident in New Zealand. ENDS For more information visit www.truscreen.com Contact Martin Dillon TruScreen Chief Executive Officer Email: martindillon@truscreen.com About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-inf End CA:00324528 For:TRU Type:MEETING Time:2018-09-27 16:08:16